Stay updated with breaking news from Croix Jarry. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell
CELLECTIS A corporation with a share capital of 2,779,188.40 euros Headquarters: 8, rue de la Croix Jarry - 75013 Paris ... | June 1, 2023
NOTICE OF MEETING COMBINED GENERAL MEETING OF SHAREHOLDERS OF JUNE 27, 2023 The shareholders are hereby informed that... | May 23, 2023
23.05.2022 - NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) - Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it ...